ClariVest Asset Management’s Celldex Therapeutics CLDX Stock Holding History

ClariVest Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-33,894	Closed	-$1.15M	–	769
2023 Q2	$1.15M	Sell	33,894 -26,114	-44%	-$880K	0.06%	221
2023 Q1	$2.16M	Sell	60,008 -12,328	-17%	-$532K	0.1%	163
2022 Q4	$3.23M	Sell	72,336 -583	-0.8%	-$20.8K	0.16%	115
2022 Q3	$2.05M	Buy	72,919 +56,519	+345%	+$1.73M	0.1%	162
2022 Q2	$442K	Hold	16,400	–	–	0.02%	389
2022 Q1	$559K	Sell	16,400 -2,300	-12%	-$73.5K	0.02%	368
2021 Q4	$722K	Sell	18,700 -14,600	-44%	-$636K	0.02%	379
2021 Q3	$1.8M	Sell	33,300 -200	-0.6%	-$9.38K	0.06%	246
2021 Q2	$1.12M	Buy	+33,500	New	+$920K	0.04%	279

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

ClariVest Asset Management's CLDX Position: Q3 2023 in Review

ClariVest Asset Management sold out of Celldex Therapeutics (CLDX) in Q3 2023, closing a stake of 33,894 shares — an estimated $1.15M sold.

ClariVest Asset Management first reported a position in CLDX in Q2 2021 and held it in 9 quarters. The position peaked at $3.23M in Q4 2022. 144 funds tracked by Wall St. Rank hold CLDX as of Q3 2023.

ClariVest Asset Management reported no remaining Celldex Therapeutics position as of Q3 2023 after selling out during the quarter.
ClariVest Asset Management sold 33,894 Celldex Therapeutics shares in Q3 2023, an estimated $1.15M.
ClariVest Asset Management first reported a position in Celldex Therapeutics in Q2 2021 and held it in 9 quarters.
ClariVest Asset Management's Celldex Therapeutics position peaked at $3.23M in Q4 2022.
144 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2023.

Based on ClariVest Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.